Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 2/20 | 0.36 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7465098 | 0.84 | ECE1 (0.42) | GGPS1FDPSCYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL12582857 | 0.77 | CA1 (0.41) | ALDH1A1ECE1PSMB5 | |
| SCHEMBL7449899 | 0.77 | GGPS1 (0.36) | GGPS1FDPSCYP2D6CYP2C19 | |
| SCHEMBL15055259 | 0.76 | KDM4E (0.38) | GGPS1FDPSCYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6183151 | 0.75 | SLC1A3 (0.52) | — | |
| SCHEMBL6151365 | 0.74 | PSMB5 (0.49) | CYP2D6CYP2C19ALDH1A1PSMB5 | |
| SCHEMBL19545559 | 0.72 | ALDH1A1 (0.42) | ALDH1A1ECE1PSMB5 | |
| SCHEMBL10768344 | 0.72 | CYP2D6 (0.39) | GGPS1FDPSCYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL7480181 | 0.71 | ALDH1A1 (0.40) | GGPS1FDPSALDH1A1ECE1 | |
| SCHEMBL6722031 | 0.70 | CYP2D6 (0.44) | CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | GGPS1 3122/4885FDPS 1919/4885CYP2D6 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.